Multi-provincial Cohort for Hypertension in China
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 30,000
- 试验地点
- 6
- 主要终点
- Composite end point of major cardiovascular and cerebrovascular events
研究概览
简要总结
The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of hypertension
- •over 18 years old
- •ti sign the informed consent
排除标准
- •with life-threatening severe disease, such as severe tumor or AIDs
- •pregnancy or lactating women,or plan to pregnant within half a year,
- •with severe mental disorders
- •participating in clinical trials
研究组 & 干预措施
Hospital based hypertension cohort
干预措施: Antihypertensive Agents (Drug)
Hospital based hypertension cohort
干预措施: Cardiovascular risk factors (Other)
Community based hypertension cohort
干预措施: Antihypertensive Agents (Drug)
Community based hypertension cohort
干预措施: Cardiovascular risk factors (Other)
结局指标
主要结局
Composite end point of major cardiovascular and cerebrovascular events
时间窗: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Composite end point of major cardiovascular and cerebrovascular events
次要结局
- New-onset of cardiovascular events(From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year)
- Total death(From date of enrollment until date of death from all cause, assessed up to 3 year)
- New-onset of stroke(From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year)
- Major bleeding(From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year)
- Atrial fibrillation(From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year)